U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Talon - 580417 - 09/09/2020
  1. Warning Letters

CLOSEOUT LETTER

Talon MARCS-CMS 580417 —

Recipient:
Recipient Name
Norman A. Shoenfeld, MD
Recipient Title
President and Owner
Talon

10625 Telge Road
Houston, TX 77095-5023
United States

nshoenfeld@taloncontrols.com
Issuing Office:
Office of Medical Device and Radiological Health Operations, Division 3

United States

Dear Dr. Shoenfeld:

The Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our Warning Letter (CMS #580417) dated August 2, 2019. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Jamie Bumpas
Acting Director, Compliance Branch
Office of Medical Device and Radiological Health Operations
Division 3 West

Cc: Clifton Wall, Quality Assurance Manager (MR)
       cwall@taloncontrols.com

Back to Top